Clinical Trial Update: Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 trial evaluating sintilimab with hypofractionated radiotherapy for MSI-H/dMMR rectal cancer; recruitment is currently open.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: West China Hospital | Conditions: Anti-PD-1 Antibody, Radiotherapy | Phase 1, Phase 2 | Status: RECRUITING